Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Garcinia cowa Bark Extract Attenuates Collagen-Induced Arthritis via Inhibition of Oxidative Stress in Rats.

International journal of rheumatic diseases·2026
Same author

Publisher Correction: Report of the Seventh Post-Kala-Azar Dermal Leishmaniasis Consortium Meeting, Kolkata, India, 28-29 November 2024.

Parasites & vectors·2026
Same author

Depth-resolved phase velocity estimation in layered tissue based on an efficient additive attention network with surface acoustic wave - optical coherence elastography.

Biomedical optics express·2026
Same author

Outcomes of Conservative and Surgical Management of Trigger Thumb in Children Up to Five Years at a Tertiary Care Center in Kolkata.

Cureus·2026
Same author

The Prevalence and Burden of Truncal Acne.

Dermatology and therapy·2026
Same author

Sterol Endoperoxides and Their Antileishmanial Effects: Influence on Viability, Oxygen Metabolism and Sterol Synthesis.

Molecules (Basel, Switzerland)·2026

Related Experiment Video

Updated: Jun 11, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.0K

Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for Localised Cutaneous Leishmaniasis.

Shalindra Ranasinghe1, Sujai Senarathne1, Vijani Somaratne2

  • 1Department of Parasitology, University of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka.

Plos Neglected Tropical Diseases
|August 29, 2024
PubMed
Summary
This summary is machine-generated.

A new Core Outcome Set (COS) for localized cutaneous leishmaniasis (LCL) was developed. This standardized tool ensures consistent assessment of LCL clinical trials and patient outcomes.

More Related Videos

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

8.2K
Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

743

Related Experiment Videos

Last Updated: Jun 11, 2026

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
11:36

Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs

Published on: April 21, 2012

22.0K
In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice
06:57

In Vivo Infection with Leishmania amazonensis to Evaluate Parasite Virulence in Mice

Published on: February 20, 2020

8.2K
Development of Leishmania Species Strains with Constitutive Expression of eGFP
10:03

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

743

Area of Science:

  • Dermatology
  • Parasitology
  • Clinical Trials Methodology

Background:

  • Localized cutaneous leishmaniasis (LCL) is a chronic, ulcerating skin disease.
  • Existing clinical trials for LCL lack standardized outcome measures, leading to inconsistent results.
  • There is a need for a consensus-driven Core Outcome Set (COS) for LCL assessment.

Purpose of the Study:

  • To establish consensus on crucial domains for assessing LCL.
  • To define specific parameters for measuring these domains.
  • To develop a comprehensive tool, a COS, for standardized clinical evaluation of LCL.

Main Methods:

  • A literature review was performed to identify existing COS and outcome measures for LCL.
  • An international collaborative approach involving expert stakeholders (n=20) from endemic regions was used to identify potential outcome domains.
  • A face-to-face multidisciplinary meeting utilized the Nominal Group Technique for judgmental validation and consensus building.

Main Results:

  • No prior COS for LCL was identified.
  • Five core outcome domains were agreed upon: Signs (lesion morphology, diameter, induration), Treatment Efficacy (lesion size change, re-epithelialization), Treatment Impact (investigator and patient visual analogue scores), and Clinical Sequelae (scarring).
  • "Clinical Cure" was defined as the primary general concept, and two open-ended questions were included to capture Health-Related Quality of Life.

Conclusions:

  • The LeishCOM_LCL tool was developed as a COS for localized cutaneous leishmaniasis.
  • This COS encompasses demographic details, agreed outcome domains, and specific measures for LCL assessment.
  • Future work will involve validation of LeishCOM_LCL and consideration of a Patient Reported Outcome Measure.